The German Joint Federal Committee requested manufacturers of machines for optical coherence tomography (OCT) to notify about their devices till 4th of October

Sep 2017

On 6th of September, the Joint Federal Committee (G-BA) released announcement for manufacturers of OCT equipment to notify about their devices till 4th of October before G-BA makes the final decision about coverage of the procedure in out-patient settings within statutory health insurance.

Previously, on 7th of July, the Institute for Quality and Efficiency in Health Care (IQWIG) published the final report of benefit assessment of optical coherence tomography (OCT) for diagnosis and treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The aim of the report was to assess benefit in comparison to other diagnostic methods (including no diagnostic) in case of initiation therapy and treatment control of intravitreal injections with anti-VEGF and steroids in patients with wAMD and DME.

Advantages and disadvantages of application of OCT in the initial diagnosis of wAMD and DME in comparison to other diagnostic procedures are unclear due to no studies were identified for this purpose. Also, no benefit and harm were identified for OCT-controlled treatment with anti-VEGF in both patient population (DME and wAMD). However, it was noticed that there was a positive effect in relation to savings of cost on OCT-controlled Treat-and-Extent (T&E) and pro-re-nata (PRN) regimens due to a decrease of disease-related costs in comparison to fixed regimen of intravitreal injections in patients with DME.

See text of decision in German here.

See IQWIG report in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Matrix-associated autologous chondrocyte implantation on the knee joint reimbursed in Germany

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

The G-BA Innovation Committee recommends transfer to standard care for three projects in Germany

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Two more health apps obtained reimbursement in Germany

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Use of a stent retriever to treat vasospasm of cerebral arteries after subarachnoid hemorrhage is being evaluated for early benefit assessment in Germany

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Health app "Cara Care for irritable bowel syndrome" obtained reimbursement in Germany

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.